Last reviewed · How we verify
Nab-paclitaxel/Paclitaxel
Nab-paclitaxel is an albumin-bound formulation of paclitaxel that stabilizes microtubules to prevent cell division, inducing apoptosis in cancer cells.
Nab-paclitaxel is an albumin-bound formulation of paclitaxel that stabilizes microtubules to prevent cell division, inducing apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer.
At a glance
| Generic name | Nab-paclitaxel/Paclitaxel |
|---|---|
| Sponsor | BioNTech SE |
| Drug class | Microtubule stabilizer / Taxane |
| Target | β-tubulin / Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to β-tubulin and stabilizes microtubule polymers, disrupting the dynamic instability required for mitotic spindle formation and cell cycle progression. The albumin-nanoparticle formulation (nab-paclitaxel) improves solubility and allows higher doses with reduced toxicity compared to conventional paclitaxel, and may enhance tumor uptake via albumin receptor-mediated endocytosis.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Pancreatic cancer
- Ovarian cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Fatigue
- Alopecia
- Myalgia/arthralgia
- Nausea
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nab-paclitaxel/Paclitaxel CI brief — competitive landscape report
- Nab-paclitaxel/Paclitaxel updates RSS · CI watch RSS
- BioNTech SE portfolio CI